DK1100792T3 - Tricycliske sulfonamider og derivater deraf som inhibitorer af matrix-metalloproteinaser - Google Patents

Tricycliske sulfonamider og derivater deraf som inhibitorer af matrix-metalloproteinaser

Info

Publication number
DK1100792T3
DK1100792T3 DK99963141T DK99963141T DK1100792T3 DK 1100792 T3 DK1100792 T3 DK 1100792T3 DK 99963141 T DK99963141 T DK 99963141T DK 99963141 T DK99963141 T DK 99963141T DK 1100792 T3 DK1100792 T3 DK 1100792T3
Authority
DK
Denmark
Prior art keywords
inhibitors
derivatives
matrix metalloproteinases
tricyclic sulfonamides
sulfonamides
Prior art date
Application number
DK99963141T
Other languages
Danish (da)
English (en)
Inventor
Patrick Michael O'brien
Joseph Armand Picard
Drago Robert Sliskovic
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DK1100792T3 publication Critical patent/DK1100792T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/28—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP with meter at substation or with calculation of charges at terminal
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/28—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP with meter at substation or with calculation of charges at terminal
    • H04M15/30—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP with meter at substation or with calculation of charges at terminal the meter or calculation of charges not being controlled from an exchange
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/31—Distributed metering or calculation of charges
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/49—Connection to several service providers
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/80—Rating or billing plans; Tariff determination aspects
    • H04M15/8044—Least cost routing
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/83—Notification aspects
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/01—Details of billing arrangements
    • H04M2215/0168—On line or real-time flexible customization or negotiation according to wishes of subscriber
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/42—Least cost routing, i.e. provision for selecting the lowest cost tariff
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/46—Connection to several service providers
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/74—Rating aspects, e.g. rating parameters or tariff determination apects
    • H04M2215/745—Least cost routing, e.g. Automatic or manual, call by call or by preselection
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/82—Advice-of-Charge [AOC], i.e. notify subscriber of charges/cumulative charge; meter at the substation
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/92—Autonomous calculations of charges in terminal, i.e. meter not controlled from exchange
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/96—Distributed calculation of charges, e.g. in different nodes like for mobiles between HLR and VLR, or between the terminal and the billing function

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Signal Processing (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
DK99963141T 1998-07-30 1999-06-02 Tricycliske sulfonamider og derivater deraf som inhibitorer af matrix-metalloproteinaser DK1100792T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9500698P 1998-07-30 1998-07-30

Publications (1)

Publication Number Publication Date
DK1100792T3 true DK1100792T3 (da) 2004-07-05

Family

ID=22248526

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99963141T DK1100792T3 (da) 1998-07-30 1999-06-02 Tricycliske sulfonamider og derivater deraf som inhibitorer af matrix-metalloproteinaser

Country Status (32)

Country Link
US (2) US6420408B1 (fr)
EP (1) EP1100792B1 (fr)
JP (1) JP2002521478A (fr)
KR (1) KR20010072089A (fr)
CN (1) CN1310716A (fr)
AP (1) AP2001002037A0 (fr)
AT (1) ATE261954T1 (fr)
AU (1) AU758619B2 (fr)
BG (1) BG105185A (fr)
BR (1) BR9912600A (fr)
CA (1) CA2335077A1 (fr)
DE (1) DE69915634T2 (fr)
DK (1) DK1100792T3 (fr)
EA (1) EA200100158A1 (fr)
EE (1) EE200100063A (fr)
ES (1) ES2216614T3 (fr)
GE (1) GEP20033052B (fr)
HR (1) HRP20010078A2 (fr)
HU (1) HUP0102714A3 (fr)
ID (1) ID27192A (fr)
IL (1) IL140746A0 (fr)
IS (1) IS5810A (fr)
NO (1) NO20010479D0 (fr)
NZ (1) NZ509439A (fr)
OA (1) OA11589A (fr)
PL (1) PL345776A1 (fr)
PT (1) PT1100792E (fr)
SK (1) SK1192001A3 (fr)
TR (1) TR200100239T2 (fr)
WO (1) WO2000006561A1 (fr)
YU (1) YU6701A (fr)
ZA (1) ZA200100455B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6846799B1 (en) 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
MXPA01013171A (es) 2001-02-14 2004-05-21 Warner Lambert Co Inhibidores triciclicos de sulfonamida de metaloproteinasa de matriz.
CN1304390C (zh) * 2001-08-03 2007-03-14 先灵公司 新颖的γ—分泌酶抑制剂
US20040235957A1 (en) * 2001-10-12 2004-11-25 David Bleakman Use of sulfonamide derivatives as pharmaceuticals compounds
KR100966705B1 (ko) * 2001-12-20 2010-06-29 브리스톨-마이어스 스큅 컴퍼니 β-아밀로이드 저해제로서의α-(Ν-술폰아미도)아세트아미드 유도체
IL165265A0 (en) * 2002-06-11 2005-12-18 Wyeth Corp Substituted phenylsulfonamide inhibitors of beta amyloid production
EP1530467A2 (fr) * 2002-07-17 2005-05-18 Warner-Lambert Company LLC Combinaison d'un inhibiteur carboxylique allosterique de metalloproteinase-13 de matrice et de celecoxibe ou de valdecoxibe
US20050095267A1 (en) * 2002-12-04 2005-05-05 Todd Campbell Nanoparticle-based controlled release polymer coatings for medical implants
EP1594459B1 (fr) 2002-12-30 2010-02-17 Angiotech International Ag Liberation de medicaments a partir d'une composition polymere a gelification rapide
WO2004089294A2 (fr) 2003-04-04 2004-10-21 Incyte Corporation Compositions, procedes et kits relatifs au clivage de her-2
EP2330132B1 (fr) 2003-04-04 2013-08-14 Yeda Research and Development Co. Ltd. Anticorps contre MMP2 ou MMP9 et compositions pharmaceutiques contenant ces anticorps utiles pour inhiber l'activité de cettes métalloprotéines
WO2005061448A1 (fr) * 2003-12-24 2005-07-07 Monash University Compositions et methodes de traitement d'affections vasculaires
US20060112494A1 (en) * 2004-12-01 2006-06-01 David Oppong Method of protecting an animal skin product from metalloproteinase activity
US8324355B2 (en) 2007-02-23 2012-12-04 Yeda Reearch and Development Co. Ltd Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
US8012947B2 (en) * 2007-03-15 2011-09-06 Hospital For Special Surgery Methods and compositions for promoting wound healing
US20090285840A1 (en) * 2008-04-29 2009-11-19 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Methods for treating pathological neovascularization
CA2676946A1 (fr) 2009-08-28 2011-02-28 Lucie Peduto Inhibiteurs de l'enzyme adam12 et leur utilisation contre la fibrose induite par l'inflammation
CN103249719A (zh) 2010-09-24 2013-08-14 兰贝克赛实验室有限公司 基质金属蛋白酶抑制剂
EP3410849B1 (fr) 2016-02-05 2023-07-05 Institut Pasteur Utilisation d'inhibiteurs d'adam12 comme adjuvants dans les traitement antitumoraux
CN114981251B (zh) * 2020-01-21 2023-11-21 深圳信立泰药业股份有限公司 一种二苯并呋喃类衍生物组织蛋白酶k抑制剂及其制备方法和医药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH517064A (de) * 1969-07-09 1971-12-31 Ciba Geigy Ag Verfahren zur Herstellung von neuen Aryloxy- und Arylthioessigsäurederivaten
CH530388A (de) * 1970-03-20 1972-11-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Aryloxy- und Arylthioalkansäureamiden
PH31294A (en) * 1992-02-13 1998-07-06 Thomae Gmbh Dr K Benzimidazolyl derivatives, pharmaceutical compositions containing these compounds and process for preparing them.
ATE206416T1 (de) 1995-06-02 2001-10-15 Warner Lambert Co Trizyklische verbindungen als matrix- metalloproteinase inhibitoren
US5883940A (en) 1996-07-01 1999-03-16 Teledynamics Group, Inc. Interactive method and apparatus for the generation of leads
ATE282602T1 (de) 1996-08-16 2004-12-15 Warner Lambert Co Buttersäure matrix-metalloproteinase-inhibitoren
WO1998009957A1 (fr) * 1996-09-04 1998-03-12 Warner-Lambert Company Composes et procede destines a l'inhibition de metalloproteases matricielles
EP0931045A1 (fr) * 1996-09-04 1999-07-28 Warner-Lambert Company Inhibiteurs de metalloproteinases matricielles et leurs utilisations pharmaceutiques
BR9712525A (pt) * 1996-10-16 1999-10-19 American Cyanamid Co O preparo e uso de ácidos orto-sulfonamido aril hidrox‰micos como inibidores da metaloproteinase matricial e da tace

Also Published As

Publication number Publication date
NO20010479L (no) 2001-01-29
EA200100158A1 (ru) 2001-08-27
ZA200100455B (en) 2002-01-16
BG105185A (en) 2002-04-30
ES2216614T3 (es) 2004-10-16
YU6701A (sh) 2003-12-31
JP2002521478A (ja) 2002-07-16
EP1100792B1 (fr) 2004-03-17
HUP0102714A3 (en) 2003-01-28
SK1192001A3 (en) 2002-02-05
NZ509439A (en) 2002-10-25
OA11589A (en) 2004-07-30
GEP20033052B (en) 2003-08-25
AP2001002037A0 (en) 2001-03-31
EP1100792A1 (fr) 2001-05-23
ATE261954T1 (de) 2004-04-15
DE69915634D1 (de) 2004-04-22
NO20010479D0 (no) 2001-01-29
US6420408B1 (en) 2002-07-16
PT1100792E (pt) 2004-08-31
DE69915634T2 (de) 2004-08-12
TR200100239T2 (tr) 2001-05-21
US20020169164A1 (en) 2002-11-14
CN1310716A (zh) 2001-08-29
US6492422B2 (en) 2002-12-10
KR20010072089A (ko) 2001-07-31
HUP0102714A2 (hu) 2002-01-28
EE200100063A (et) 2002-06-17
IL140746A0 (en) 2002-02-10
CA2335077A1 (fr) 2000-02-10
PL345776A1 (en) 2002-01-02
ID27192A (id) 2001-03-08
AU758619B2 (en) 2003-03-27
WO2000006561A1 (fr) 2000-02-10
BR9912600A (pt) 2001-05-02
AU4329299A (en) 2000-02-21
IS5810A (is) 2001-01-12
HRP20010078A2 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
DK1100792T3 (da) Tricycliske sulfonamider og derivater deraf som inhibitorer af matrix-metalloproteinaser
DK0923585T3 (da) Phosphinatbaserede inhibitorer af matrixmetalloproteinaser
NO20005265D0 (no) Substituerte benzamider, deres fremstilling og anvendelse som inhibitorer av cystin-proteaser
NO991922D0 (no) Heteroarylsuccinamider og deres anvendelse som metalloproteinaseinhibitorer
NO992492D0 (no) Benzamidoaldehyder og deres anvendelse som cystein-protease-inhibitorer
DK1133477T3 (da) Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
NO996313D0 (no) Nye amidinoderivater og deres anvendelse som trombininhibitorer
NO20026010D0 (no) Substituerte quinazolinderivater og deres anvendelse som inhibitorer
DK1288206T3 (da) Substituerede benzensulfonamidderivater som prolægemidler af COX-2-inhibitorer
DK1347955T3 (da) Nye mandelsyrederivater og deres anvendelse som throbin-hæmmere
NO986180D0 (no) Nye amidinoderivater og deres anvendelse som trombininhibitorer
DK1086076T3 (da) Sulfonamidinhibitorer af aspartylprotease
DK1170288T3 (da) Diphenylurinstofderivater og deres anvendelse som alfa2/5-HT2c-antagonister
DK0989121T3 (da) Substituerede benzamider og deres anvendelse som immunmodulatorer
DK1686113T3 (da) Inhibitorer af aspartylprotease
NO20026262L (no) Cyklopentyl-substituerte glutaramidderivater som inhibitorer av nöytral endopeptidase
NO20042719L (no) Substituerte 2-amino-cykloalkankarboksamider og deres anvendelse som protease-inhibitorer
DK1047450T3 (da) Kombinationer af ACE-inhibitorer og MMP-inhibitorer
NO20034995D0 (no) Aromatiske sulfonhydroksymater og deres anvendelse som proteaseinhibitorer
IS5772A (is) Þalazín (phthalazine) afleiður af fosfódíesterasa4 lötum
DK1150996T3 (da) Nye amidinobenzylaminderivater og deres anvendelse som thrombin-inhibitorer
DK0928291T3 (da) 3-Mercaptoacetylamino-1,5-substituerede 2-oxo-azepanderivater, der er nyttige som inhibitorer af matrixmetalloproteinase
NO20023956L (no) Priperidin- og piperazinsubstituerte N-hydroksyformamider som inhibitorer av metalloproteinaser
DK1299365T3 (da) 2-aminothiazolinderivater og deres anvendelse som inhibitorer for NO-synthase
DK1147101T3 (da) Omvendt-hydroxamat-inhibitorer af matrix-metalloproteinaser